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CONCLUSIONS: In a studied period, NICE published more positive recommenda-
tions for cancer drug technologies than AHTAPoL. The contradictory 
recommendations prevailed in the group of drug technologies appraised by both 
jurisdictions.
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KNOWLEDGE TRANSFER REGARDING CANCER SCREENING BASED ON 
INTERESTS OF DIFFERENT TARGET POPULATIONS
Hamashima C
National Cancer Center of Japan, Tokyo, Japan
OBJECTIVES: To develop targeted leaﬂ ets regarding cancer screening guidelines that 
take account the knowledge required by different target groups. METHODS: Before 
developing leaﬂ ets, public interest data regarding cancer screening were collected by 
the problem solving model (the so-called KJ method developed for ﬁ eld surveys in 
Japan). The KJ method includes two steps: label making of information corresponded 
to speciﬁ c issues and grouping similar concepts. Contents of leaﬂ ets were edited based 
on the results of the KJ methods but changed in the ﬁ nal version according to discus-
sions at a committee meeting involving public members. We compared the results of 
the KJ method and contents of the ﬁ nal version of the leaﬂ ets for the following groups: 
cervical cancer screening targeted at 20-year-old subjects (ﬁ rst group), cervical cancer 
screening targeted at subjects aged 30 years and older (second group), and 
colorectal cancer screening targeted at subjects aged 40 years and older (third 
group). RESULTS: Common interests among the three groups included targeting 
cancer and screening methods. Although the KJ method revealed that the ﬁ rst 
group expected broad information, in the ﬁ nal version of the leaﬂ et, only basic infor-
mation regarding participation in cancer screening programs remained. The ﬁ nal 
versions in group 2 and 3 almost corresponded to the ﬁ rst interest of an actual plan 
to participate in a screening program including details of the screening methods as 
well as physical and ﬁ nancial burden expected. Although information regarding the 
harm of cancer screening was initially included according to the results of the KJ 
methods in the second and third groups, there was no expectation in the ﬁ rst group. 
CONCLUSIONS: A targeted leaﬂ et is a powerful tool to share knowledge regarding 
cancer screening. We must understand the expectations of different target groups and 
prepare appropriate leaﬂ ets that support the decision to take part in cancer 
screening.
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REASONS FOR DISCONTINUATION OF HORMONAL THERAPY IN 
BREAST CANCER PATIENTS ACROSS FIVE EUROPEAN COUNTRIES
Petrilla AA, Ferruﬁ no CP
IMS Health, Falls Church, VA, USA
OBJECTIVES: Recent evidence suggests that many breast cancer patients discontinue 
their hormonal therapy treatment regimen before the end of the recommended treat-
ment period, but reasons for treatment discontinuation are not well understood. 
Therefore, we examined reasons for hormonal therapy discontinuation in a European 
treatment cohort of female breast cancer (BC) patients. METHODS: Female patients 
ages 21+ with a diagnosis of BC between January 2006 and December 2008 were 
identiﬁ ed within IMS Oncology AnalyzerTM which provides retrospective, cross-sec-
tional, cancer-treatment data from 14 countries including France, Germany, Italy, 
Spain, and the United Kingdom and encompasses over 60,000 de-identiﬁ ed BC patient 
records from a physician panel of nearly 800 doctors in the EU5. Patients within the 
EU5 with early-stage BC (stages I-IIIa) who received hormonal therapy and for whom 
their physician provided a reason for discontinuing ﬁ rst course of therapy were 
included in the study. Patients enrolled in clinical trials were excluded. Reasons for 
discontinuation of therapy include course completion, progression of disease, stabiliza-
tion of disease, adverse events, terminal outlook, poor performance, and patient’s 
choice. RESULTS: 10,949 patients were identiﬁ ed. Approximately 57.2% discontin-
ued their ﬁ rst course of hormonal therapy prior to course completion. Of these 
patients, the top reasons for early discontinuation included progression of the disease 
(59.5%), adverse events (21.7%) and patient choice (10.1%). Mean duration of 
therapy for all patients was 95.4 months (range 45.5–152.1). Time to discontinuation 
was signiﬁ cantly shorter for those who quit due to Aes than those who quit by choice 
(36.2 months vs. 57.8 months, P < 0.0001). Of patients that discontinued due to AEs, 
hot ﬂ ushes (46.1%), pain (19.1%), and nausea and vomiting (14.0%) were the most 
commonly reported events. CONCLUSIONS: This analysis in a real world setting 
provides new insight into reasons for early discontinuation of hormonal therapy in 
the EU5.
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TREATMENT DECISION CHANGE WITH 21-GENE RECURRENCE SCORE 
IN PATIENTS WITH EARLY STAGE BREAST CANCER (ESBC): A 
META-ANALYSIS
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OBJECTIVES: The 21-gene Recurrence Score® (RS) is a validated assay for estimating 
a woman’s recurrence risk and chemotherapy beneﬁ t after the diagnosis of estrogen 
receptor positive (ER+), ESBC. We conducted a meta-analysis of RS’s inﬂ uence on 
treatment recommendations/decisions in lymph node negative (LN-) disease. 
METHODS: Literature was abstracted on cohort studies that reported the change in 
the recommendation or actual use of adjuvant chemotherapy (CT) for patients with 
ER+, LN-, ESBC before and after the RS. Outcomes evaluated were: treatment decision 
change from 1) CT plus hormone therapy (HT) to HT-only or 2) HT-only to CT plus 
HT. Actual treatment change was used when available. Reductions in the relative and 
absolute CT use associated with the RS were computed with Review Manager (5 
Version 5.0.24; Copenhagen: The Nordic Cochrane Centre, the Cochrane Collabora-
tion 2008). The relative change in CT was calculated as a before-to-after ratio of 
proportion of patients recommended or received CT, weighted by study sample size. 
RESULTS: Seven published studies (n = 912 patients) were eligible for the meta-
analysis. One was a prospective physician survey; six were retrospective chart reviews. 
a total of 569 (62%) patients were recommended CT prior to RS testing. After RS 
testing, 272 (30%) patients were recommended or received CT. In six of seven studies 
(n = 652 patients) that reported a treatment change, 212 (32%) patients switched from 
CT plus HT before RS to HT-only after RS. The absolute reduction in CT before and 
after RS testing was 30% (95% CI [−39%, −21%]). The relative reduction in CT 
before and after RS was 49% (95% CI [42%, 58%]). Estimates varied little when 
analysis omitted a single study. Limitations include heterogeneity in study designs. 
CONCLUSIONS: The meta-analysis shows consistent overall reduction in CT with 
the use of RS. 
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THE ROLE OF PATIENT SELECTION CRITERIA IN IDENTIFYING 
OVARIAN CANCER PATIENTS
Meyers J1, Mitra D1, Doan J2, Leeﬂ ang C3
1RTI Health Solutions, Research Triangle Park, NC, USA; 2Genentech, Inc, South San 
Francisco, CA, USA; 3IMS Health, Watertown, MA, USA
BACKGROUND: Retrospective claims databases are commonly used in outcomes 
research. Since physician charts are rarely available to conﬁ rm diagnoses, care must 
be taken when choosing patient populations. OBJECTIVES: To show how patient 
selection criteria affects sample size and chemotherapy treatment rates using an 
ovarian cancer (OC) population. METHODS: Patients were initially selected if 
they met the following inclusion criteria: at least one diagnosis of OC (ICD-9-CM 
codes 183.0x) between 1/1/2002 and 12/31/2007 (ﬁ rst OC diagnosis date termed 
index), 6 months pre-index and 12 months post-index eligibility, and no OC diagnosis 
in the 6 months pre-index. Additional criteria were imposed to further reﬁ ne the 
sample and assess variations in chemotherapy treatment rates. First, patients were 
required to have at least two diagnoses of OC at least 14 days apart. Next, patients 
were required to have both OC diagnoses on a record labeled as medical, surgical, 
facility, or pharmacy (i.e., ancillary records were excluded). RESULTS: A total of 
37,172 patients had at least one diagnosis of OC. Of those, 16,418 had 6 months 
pre-index and 12 months post-index eligibility with no pre-index OC diagnoses. In 
this population, 26% of patients received chemotherapy. When patients were also 
required to have one additional OC diagnosis at least 14 days from index, the sample 
size dropped to 7431 patients, of whom 47% received chemotherapy. When OC 
diagnoses on ancillary records were excluded, a total of 6213 patients were identiﬁ ed, 
of whom 52% received chemotherapy. CONCLUSIONS: Chemotherapy rates among 
OC patients varied signiﬁ cantly by the sample selection criteria used. Care must be 
taken to identify the correct patient sample in any retrospective database analysis since 
selection criteria affect the appropriateness of the sample, and thus the study 
results.
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SYSTEMATIC OVERVIEW
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OBJECTIVES: To provide an overview on published decision-analytic models evaluat-
ing various treatment strategies in chronic myeloid leukemia (CML). We sought to 
describe and analyze the structural and methodological approaches used and to derive 
recommendations for future CML models. METHODS: We performed a systematic 
literature review in electronic databases (Medline/PreMedline, EconLit, EMBASE, and 
others) to identify published studies evaluating CML treatment strategies using math-
ematical decision models. The models were required to compare different treatment 
strategies and to comprise relevant clinical health outcomes such as life-years gained 
or QALYs over a deﬁ ned time horizon and population. We used standardized forms 
for data extraction, description of study design, methodological framework, and data 
sources. RESULTS: We identiﬁ ed 14 different decision-analytic modeling studies, 
among which, 13 included economic evaluations. The modeling approaches varied 
substantially and comprised decision trees, Markov models, Monte Carlo simulations, 
and mathematical equations. Time horizons ranged from 2 years to lifetime. Health 
outcomes included survival, life expectancy, and QALYs. Compared treatment strate-
gies comprised bone or blood marrow transplantation, conventional chemotherapy, 
interferon-alpha, and ﬁ rst-generation tyrosine kinase inhibitor (TKI) imatinib. None 
of the models evaluated comprehensive personalized medicine strategies or second 
generation TKI (e.g., nilotinib, dasatinib). Only few models were validated using 
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independent data. CONCLUSIONS: We found several well-designed models for dif-
ferent CML treatment strategies. However, the quality of reporting varied substan-
tially. We recommend that future models should include novel treatment options, 
subgroup evaluations for a more personalized decision making, and validation using 
independent data. Already available models with a short time horizon could be 
updated with new survival data.
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EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELING: 
IN SEARCH OF A STANDARD
Ekman M1, Charbonneau C2, Ramsberg J1, Jonsson L1, Sandin R3, Jonsson B4, Drummond 
M5, Weinstein MC6
1i3 Innovus, Stockholm, Sweden; 2Pﬁ zer, Inc, New York, NY, USA; 3Pﬁ zer Oncology, 
Sollentuna, Stockholm, Sweden; 4Stockholm School of Economics, Stockholm, Sweden; 
5University of York, York, UK; 6Harvard School of Public Health, Boston, MA, USA
BACKGROUND: Extrapolation is often a key element in health economic modeling. 
Although any model should use empirical data if possible, the effects of treatments 
on long-term health outcomes are seldom observed within the follow-up time of a 
clinical study. Extrapolation over a lifetime horizon will generally be required in 
economic models where treatments have different cumulative survival at the end of 
the clinical trial. Typically, a within-trial analysis of costs and health effects, in which 
outcomes are truncated at the conclusion of the trial, will be overly conservative. 
OBJECTIVES: The purpose of this study is to compare different methods of extrapola-
tion in the context of examples concerning oncology, although the principles apply 
across all therapeutic areas. METHODS: There is a set of standard assumptions 
regarding extrapolation of survival data from clinical studies, ranging from very cau-
tious (“stop-and drop”) to very optimistic (“continued beneﬁ t”). The impact of dif-
ferent assumptions regarding extrapolation is explored, and the implications are 
discussed. CONCLUSIONS: The choice of extrapolation method has signiﬁ cant 
impact on comparative clinical effects, costs, and cost-effectiveness. Based on our 
ﬁ ndings and supporting examples, we propose the following: 1) Analysts should 
perform and report results under a range of speciﬁ c standard extrapolation assump-
tions to increase comparability across studies. 2) The choice of a base-case approach 
in any particular study should be guided by knowledge about the biology of the indica-
tion under evaluation and the mechanism of action of the treatment. A case could be 
made for a reference case method of extrapolation, but we believe that sensitivity 
analysis across a standard set of possibilities is sufﬁ cient. Adherence to these modeling 
practices will contribute to increased transparency in modeling and hence potentially 
to a greater conﬁ dence among health-care decision-makers in the results from cost-
effectiveness analyses building on modeling and extrapolation.
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EXTENDING FIXED EFFECT MODELS TO CENSORED COST DATA
Baser O1, Yuce H2
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OBJECTIVES: Challenges in analyzing cost data include addressing skewness in cost 
distributions, observed and unobserved heterogeneity across samples, and even more 
challenging complexities due to censoring. We combined generalized random effect 
models with inverse probability weighted (IPW) estimation techniques to address those 
challenges in a single model. METHODS: Generalized ﬁ xed effect models have been 
used with weights that are calculated as inverse due to probability being uncensored. 
The Gaussian family and log link function was chosen and we applied a test to see if 
possibly censoring bias exists. We also calculated the deviation from the consistent 
value if standard pooled ordinary least squares were used. RESULTS: A total of 4824 
observations were used in the analysis. We obtained Medicare claim ﬁ les for the 2 
years following patients’ lung cancer diagnosis. Costs had high kurtosis and skewness. 
Moreover, 30% of the cases were censored, and therefore, their annual costs were not 
observed. The total cost of all care was $63,000 for the 2 years following a lung cancer 
diagnosis and $57,000 for incomplete cases. Results signiﬁ cantly diverged from the 
standard regression model (P = 0.000). CONCLUSIONS: This paper applied inverse 
probability weighted estimation and ﬁ xed effect panel data models to an inception 
cohort of patients newly diagnosed with lung cancer. Our ﬁ ndings suggest that stan-
dard regression models yield inconsistent estimators due to censoring bias. The IPW 
least square estimation method removes that bias.
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THE ECONOMICS OF CHRONIC MYELOGENOUS LEUKEMIA: A 
COMPARISON OF MODELING APPROACHES
Taylor MJ
University of York, York, UK
OBJECTIVES: Chronic myelogenous leukemia (CML) is a progressive disease which 
arises from damage to the DNA of a stem cell in the bone marrow. This results in the 
uncontrolled growth of white blood cells which, in turn, can lead to severe impairment 
of an individual’s functioning. The National Institute for Health and Clinical Excel-
lence (NICE) models the costs and beneﬁ ts of medicines. The structure of these models 
is not prespeciﬁ ed and wide variations are often observed, both in the model’s choice 
of input parameters and in the structure of the modeling approach. While there is no 
such thing as a “correct” model, it is important that different models are compared 
and critiqued in order to identify any particular strengths and weaknesses of differing 
approaches. METHODS: A review was undertaken, identifying existing published 
models for CML. The data sources and choice of inputs were compared across each 
model and presented in a comparative table. Furthermore, the different approaches 
to model structure were examined, and attempts were made to explore the conse-
quences of each approach on the models, costs, effectiveness, and cost-effectiveness 
ﬁ ndings. RESULTS: The approaches to modeling CML vary signiﬁ cantly between 
different studies. While different data sources are utilitized in each model, this can 
usually be explained by emerging data which were not available to other researchers. 
However, the overall approach to modeling the disease varied considerably across 
each study. Model structures and assumptions for long-term outcomes were key 
drivers of the cost-effectiveness results in each model, but were often based on con-
trasting and contradicting approaches. CONCLUSIONS: This review has highlighted 
signiﬁ cant variation in approaches to modelling CML. It is recommended that long-
term follow-up from previously published trials should be used to predict the likely 
outcomes associated with shorter-term outcomes, such as treatment response.
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INFLATION ANALYSIS AS A TOOL TO ASSESS COST-EFFECTIVENESS 
OF CANCER TREATMENT
Eliseeva E, Apanasevich V, Solodyankina T
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OBJECTIVES: Cost-effectiveness of chronic diseases drug-therapy is estimated with 
the help of various pharmacoeconomic analysis methods. Cost-effectiveness analysis, 
cost minimization analysis, cost-utility analysis, and cost-effectiveness analysis are 
used most often. We have proposed a modiﬁ cation of the cost-effectiveness analysis, 
which makes possible to record patient’s losses during treatment. Inﬂ ation coefﬁ cient 
K and its average value—Kmed may be more reliable tool in assessing the cost-
effectiveness of treatment of recurrent disease. METHODS: Formula evaluation of the 
effectiveness can be expressed as Kt &die;T DC(M/Nt), where k—coefﬁ cient of effec-
tiveness of treatment at time t DC—amount invested in the treatment of one person 
M—number of patients in the beginning of treatment (original group) N—number of 
patients at the time T t—regular interval, running on the account (month, day, year, 
etc.) RESULTS: Analysis of the coefﬁ cient K shows a tendency to increase with an 
increase in DC price for the treatment or—on decreasing the number of patients N, 
remaining in the group. As the period t becomes longer, entire formula is decreasing 
(inﬂ ation). The average coefﬁ cient k meaning is calculated according the formula 
Kmed &die;T ∑ Kt/t. Coefﬁ cient shows the average cost of one free of recurrence 
month in one patient from the group. The number of patients in group N decreases 
as a disease recurs, which leads to Kmed increase because of reallocating funds spent 
on chronic patients for the rest of patients. CONCLUSIONS: The study of economic 
efﬁ ciency through inﬂ ationary coefﬁ cient K, we have proposed, is a sensitive method 
for estimating treatment costs, and may prove to be a reliable tool for cost-effectiveness 
analysis of chronic patient drug therapy.
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SYSTEM” (CHES)
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OBJECTIVES: Studies evaluating computer-aided routinely assessment of patient-
reported outcomes (PRO) suggest important beneﬁ ts for physicians, patients, and their 
treatment. This project’s aim was developing a ﬂ ag system for computerized detection 
of cancer patients with additional treatment needs. METHODS: The detection system 
is part of the “Computer based Health Evaluation System (CHES),” a software for 
the computerized collection, processing, and presentation of PRO data. The ﬂ ag 
system helps identify cancer patients with conspicuous subscale patterns. This includes 
cutoff values (patients marked with orange or red buttons) and signiﬁ cant changes 
over time (yellow deltas). The testing data set was derived from a longitudinal study 
on QOL (assessed using the EORTC QLQ-C30) in chemotherapy patients at an 
oncological outpatient unit. Several criteria of “relevant” changes were compared 
regarding the prevalence of such changes in the study population and their statistical 
signiﬁ cance on an individual patient level. RESULTS: QOL data of 167 cancer patients 
were analyzed (on average 5.3 assessments per patient). The 75th and 90th percentile 
showed to be useful cutoff values. Recommended thresholds of relevant QOL changes 
appear to be unduly low when considering changes in the individual patient. Based 
on empirical data, we suggest a modiﬁ ed criterion of relevant change for the EORTC 
QLQ-C30 which appears clinically and statistically more meaningful. CONCLU-
SIONS: The developed ﬂ ag system enables physicians to detect patient-reported health 
deﬁ cits (e.g., fatigue) at one glance. However, more research involving various diag-
nostic groups is needed for a more profound empirical basis for developing reﬁ ned 
criteria.
